Last 12 months
Inside the activity.
2 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 1 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2021 Filed May 27, 2021 20:36 UTC |
Stewart Christopher P.Chief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-21-036254 · doc4.xml · derivative · entry 2 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 25,000 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vest in full on December 31, 2020, subject to Reporting Person's continuous service through December 31, 2020, subject to acceleration of vesting provided in the Employment Agreement, dated as of September 1, 2020, by and between the Issuer and the Reporting Person. Read SEC document |
| May 26, 2021 Filed May 27, 2021 20:36 UTC |
Stewart Christopher P.Chief Financial Officer
|
Exercise / conversionCommon Stock | 25,000 | $0.56 | $14,000.00 |
DisclosureSEC source: 0001209191-21-036254 · doc4.xml · nonDerivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2021 Filed May 14, 2021 23:16 UTC |
Holmlin R. ErikDirector · President and CEO
|
GrantCommon Stock | 290,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032934 · doc4.xml · nonDerivative · entry 2 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,191 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. Read SEC document |
| May 12, 2021 Filed May 14, 2021 23:16 UTC |
Holmlin R. ErikDirector · President and CEO
|
GrantCommon Stock | 290,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032934 · doc4.xml · nonDerivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,191 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · balance_after: Includes: 218 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on December 10, 2018, 450 shares acquired under the ESPP on June 10, 2019, 728 shares acquired under the ESPP on December 10, 2019, 1,014 shares acquired under the ESPP on June 10, 2020 and 1,151 shares acquired under the ESPP on December 10, 2020. Read SEC document |
| May 12, 2021 Filed May 14, 2021 23:15 UTC |
OLDAKOWSKI MARKChief Operating Officer
|
GrantCommon Stock | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032932 · doc4.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,086 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · balance_after: Includes: 495 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on December 10, 2018, 1,021 shares acquired under the ESPP on June 10, 2019, 1,405 shares acquired under the ESPP on December 10, 2019, 1,199 shares acquired under the ESPP on June 10, 2020 and 1,151 shares acquired under the ESPP on December 10, 2020. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:33 UTC |
Chaubey AlkaChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $7.83 | $0.00 |
DisclosureSEC source: 0001209191-21-024792 · doc4.xml · derivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of April 1, 2021 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:33 UTC |
Stewart Christopher P.Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $7.83 | $0.00 |
DisclosureSEC source: 0001209191-21-024790 · doc4.xml · derivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of April 1, 2021 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:32 UTC |
Holmlin R. ErikDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 775,000 | $0.00 Strike: $7.83 | $0.00 |
DisclosureSEC source: 0001209191-21-024789 · doc4.xml · derivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,000 Underlying: Common Stock · 775,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of April 1, 2021 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:31 UTC |
OLDAKOWSKI MARKChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $7.83 | $0.00 |
DisclosureSEC source: 0001209191-21-024788 · doc4.xml · derivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of April 1, 2021 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| January 22, 2021 Filed Jan 25, 2021 21:24 UTC |
Stewart Christopher P.Chief Financial Officer
|
GrantCommon Stock | 8,000 | $6.00 | $48,000.00 |
DisclosureSEC source: 0001209191-21-005082 · doc4.xml · nonDerivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 F1 · kind: Acquired from the Issuer pursuant to an Underwriting Agreement dated January 20, 2021 with a closing date of January 22, 2021. The Underwriting Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:41 UTC Amendment |
Chaubey AlkaChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-20-049554 · doc4a.xml · derivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-09-01 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on August 31, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such applicable vesting date and the terms of the Issuer's 2020 Inducement Plan. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:53 UTC |
Stewart Christopher P.Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-20-049303 · doc4.xml · derivative · entry 2 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-09-01 F2 · derivative.exercise_date: The shares vest in full on December 31, 2020, subject to Reporting Person's continuous service through December 31, 2020, subject to acceleration of vesting provided in the Employment Agreement, dated as of September 1, 2020, by and between the Issuer and the Reporting Person. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:53 UTC |
Stewart Christopher P.Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-20-049303 · doc4.xml · derivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2030-09-01 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on September 1, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such applicable vesting date and the terms of the Issuer's 2020 Inducement Plan, subject to acceleration of vesting as provided for in that certain Employment Agreement, dated as of September 1, 2020, by and between the Issuer and the Reporting Person. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:43 UTC |
Chaubey AlkaChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-20-049301 · doc4.xml · derivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-09-01 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on August 31, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such applicable vesting date and the terms of the Issuer's 2020 Inducement Plan. Read SEC document |
| June 30, 2020 Filed Jul 3, 2020 00:29 UTC |
Linney YvonneDirector
|
GrantStock Option (right to buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-20-040755 · doc4.xml · derivative · entry 1 Linney Yvonne · CIK 0001810930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2029-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:31 UTC |
Mamuszka HannahDirector
|
GrantStock Option (right to buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-20-040759 · doc4.xml · derivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2029-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 30, 2020 Filed Jul 3, 2020 00:37 UTC |
Vuori Kristiina MDDirector
|
GrantStock Option (right to buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-20-040769 · doc4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2029-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 30, 2020 Filed Jul 3, 2020 00:35 UTC |
TWOMEY CHRISTOPHER JDirector
|
GrantStock Option (right to buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-20-040765 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2029-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 30, 2020 Filed Jul 3, 2020 00:32 UTC |
Luderer AlbertDirector
|
GrantStock Option (right to buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-20-040762 · doc4.xml · derivative · entry 1 Luderer Albert · CIK 0001746822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2029-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 30, 2020 Filed Jul 3, 2020 00:26 UTC |
BARKER DAVID LDirector
|
GrantStock Option (right to buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-20-040750 · doc4.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2029-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 30, 2020 Filed Jul 18, 2022 23:27 UTC Amendment |
Linney YvonneDirector
|
GrantStock Option (Right to Buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-22-042484 · doc4a.xml · derivative · entry 1 Linney Yvonne · CIK 0001810930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2030-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). F2 · derivative.expiration_date: The acquisition of the reported option was reported in a Form 4 filed on July 2, 2020, which mistakenly reported the expiration date as 06/30/2029. Read SEC document |
| June 30, 2020 Filed Jul 18, 2022 19:25 UTC Amendment |
Mamuszka HannahDirector
|
GrantStock Option (Right to Buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-22-042480 · doc4a.xml · derivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2030-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). F2 · derivative.expiration_date: The acquisition of the reported option was reported in a Form 4 filed on July 2, 2020, which mistakenly reported the expiration date as 06/30/2029. Read SEC document |
| June 30, 2020 Filed Jul 18, 2022 23:29 UTC Amendment |
Luderer AlbertDirector
|
GrantStock Option (Right to Buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-22-042485 · doc4a.xml · derivative · entry 1 Luderer Albert · CIK 0001746822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2030-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). F2 · derivative.expiration_date: The acquisition of the reported option was reported in a Form 4 filed on July 2, 2020, which mistakenly reported the expiration date as 06/30/2029. Read SEC document |
| June 30, 2020 Filed Jul 18, 2022 23:30 UTC Amendment |
TWOMEY CHRISTOPHER JDirector
|
GrantStock Option (Right to Buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-22-042486 · doc4a.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2030-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). F2 · derivative.expiration_date: The acquisition of the reported option was reported in a Form 4 filed on July 2, 2020, which mistakenly reported the expiration date as 06/30/2029. Read SEC document |
| June 30, 2020 Filed Jul 18, 2022 23:26 UTC Amendment |
Vuori Kristiina MDDirector
|
GrantStock Option (Right to Buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-22-042482 · doc4a.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2030-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). F2 · derivative.expiration_date: The acquisition of the reported option was reported in a Form 4 filed on July 2, 2020, which mistakenly reported the expiration date as 06/30/2029. Read SEC document |
| May 04, 2020 Filed May 6, 2020 18:29 UTC |
Linney YvonneDirector
|
GrantStock Option (right to buy) · Derivative | 80,923 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-20-027426 · doc4.xml · derivative · entry 1 Linney Yvonne · CIK 0001810930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,923 Underlying: Common Stock · 80,923 shares Expires 2030-05-04 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a three year period such that the option is fully vested on May 4, 2023, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| May 04, 2020 Filed May 6, 2020 14:30 UTC |
Mamuszka HannahDirector
|
GrantStock Option (right to buy) · Derivative | 80,923 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-20-027427 · doc4.xml · derivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,923 Underlying: Common Stock · 80,923 shares Expires 2030-05-04 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a three year period such that the option is fully vested on May 4, 2023, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 18:50 UTC |
TWOMEY CHRISTOPHER JDirector
|
GrantCommon Stock Warrants (right to buy) · Derivative | 45,000 | $0.01 Strike: $0.33 | $450.00 |
DisclosureSEC source: 0001209191-20-023733 · doc4.xml · derivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · C J TWOMEY & R J TWOMEY TTEES, C J & R J TWOMEY FAMILY TRUST, UAD 9/20/2002 Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2025-04-06 F1 · kind: Acquired from the Issuer pursuant to an Underwriting Agreement dated April 1, 2020 with a closing date of April 6, 2020. The Underwriting Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors. F2 · price: The total per share and accompanying common warrant price offered in the public offering is $0.33. Each share of common stock is being sold together with a common warrant to purchase one share of the Company's common stock. The public offering price, per share is $0.32 and per common warrant is $0.01. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 18:50 UTC |
TWOMEY CHRISTOPHER JDirector
|
GrantCommon Stock | 45,000 | $0.32 | $14,400.00 |
DisclosureSEC source: 0001209191-20-023733 · doc4.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · C J TWOMEY & R J TWOMEY TTEES, C J & R J TWOMEY FAMILY TRUST, UAD 9/20/2002 Disclosed balance after: 64,500 F1 · kind: Acquired from the Issuer pursuant to an Underwriting Agreement dated April 1, 2020 with a closing date of April 6, 2020. The Underwriting Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors. F2 · price: The total per share and accompanying common warrant price offered in the public offering is $0.33. Each share of common stock is being sold together with a common warrant to purchase one share of the Company's common stock. The public offering price, per share is $0.32 and per common warrant is $0.01. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 19:25 UTC |
Robinson WarrenChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-20-011299 · doc4.xml · derivative · entry 1 Robinson Warren · CIK 0001745569 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2020-02-17 F1 · derivative.exercise_date: The shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of February 18, 2020 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 00:24 UTC |
OLDAKOWSKI MARKChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-20-011298 · doc4.xml · derivative · entry 1 Borodkin Mark · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 18, 2020 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 00:23 UTC |
Holmlin R. ErikDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 290,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-20-011297 · doc4.xml · derivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 18, 2020 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 00:22 UTC |
Adams HeatherChief Administrative Officer
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-20-011296 · doc4.xml · derivative · entry 1 Adams Heather · CIK 0001803671 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 18, 2020 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 19:15 UTC |
TWOMEY CHRISTOPHER JDirector
|
GrantCommon Stock Warrants (right to buy) · Derivative | 9,500 | $0.01 Strike: $0.86 | $95.00 |
DisclosureSEC source: 0001209191-19-054082 · doc4.xml · derivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · C J TWOMEY & R J TWOMEY TTEES, C J & R J TWOMEY FAMILY TRUST, UAD 9/20/2002 Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2024-10-23 F1 · kind: Acquired from the Issuer pursuant to an Underwriting Agreement dated October 21, 2019 with a closing date of October 23, 2019. The Underwriting Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors. F2 · price: The total per share and accompanying common warrant price offered in the public offering is $0.86. Each share of common stock is being sold together with a common warrant to purchase one share of the Company's common stock. The public offering price, per share is $0.85 and per common warrant is $0.01. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 19:15 UTC |
TWOMEY CHRISTOPHER JDirector
|
GrantCommon Stock | 9,500 | $0.85 | $8,075.00 |
DisclosureSEC source: 0001209191-19-054082 · doc4.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · C J TWOMEY & R J TWOMEY TTEES, C J & R J TWOMEY FAMILY TRUST, UAD 9/20/2002 Disclosed balance after: 19,500 F1 · kind: Acquired from the Issuer pursuant to an Underwriting Agreement dated October 21, 2019 with a closing date of October 23, 2019. The Underwriting Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors. F2 · price: The total per share and accompanying common warrant price offered in the public offering is $0.86. Each share of common stock is being sold together with a common warrant to purchase one share of the Company's common stock. The public offering price, per share is $0.85 and per common warrant is $0.01. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:38 UTC |
Zhou QuanDirector · 10% owner
|
GrantStock Option (right to buy) · Derivative | 21,911 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001209191-19-035909 · doc4.xml · derivative · entry 1 Zhou Quan · CIK 0001747536 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,911 Underlying: Common Stock · 21,911 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 6, 2020, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:37 UTC |
WANG JUNFENGDirector · 10% owner
|
GrantStock Option (right to buy) · Derivative | 21,911 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001209191-19-035907 · doc4.xml · derivative · entry 1 WANG JUNFENG · CIK 0001748417 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,911 Underlying: Common Stock · 21,911 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 6, 2020, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:36 UTC |
TWOMEY CHRISTOPHER JDirector
|
GrantStock Option (right to buy) · Derivative | 21,911 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001209191-19-035905 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,911 Underlying: Common Stock · 21,911 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 6, 2020, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:34 UTC |
Cai DarrenDirector
|
GrantStock Option (right to buy) · Derivative | 21,911 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001209191-19-035900 · doc4.xml · derivative · entry 1 Cai Darren · CIK 0001746824 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,911 Underlying: Common Stock · 21,911 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 6, 2020, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:35 UTC |
Luderer AlbertDirector
|
GrantStock Option (right to buy) · Derivative | 21,911 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001209191-19-035903 · doc4.xml · derivative · entry 1 Luderer Albert · CIK 0001746822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,911 Underlying: Common Stock · 21,911 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 6, 2020, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:31 UTC |
Vuori Kristiina MDDirector
|
GrantStock Option (right to buy) · Derivative | 30,274 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001209191-19-035894 · doc4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,274 Underlying: Common Stock · 30,274 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a three year period such that the option is fully vested on June 6, 2022, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:33 UTC |
BARKER DAVID LDirector
|
GrantStock Option (right to buy) · Derivative | 21,911 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001209191-19-035898 · doc4.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,911 Underlying: Common Stock · 21,911 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 6, 2020, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| March 01, 2019 Filed Mar 6, 2020 14:08 UTC |
Robinson WarrenChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001209191-20-016872 · doc4.xml · derivative · entry 1 Robinson Warren · CIK 0001745569 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of March 1, 2019 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| March 01, 2019 Filed Mar 6, 2020 19:09 UTC |
Ward Michael JamesFormer Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001209191-20-016873 · doc4.xml · derivative · entry 1 Ward Michael James · CIK 0001569975 · Former Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of March 1, 2019 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| March 01, 2019 Filed Mar 6, 2020 19:07 UTC |
OLDAKOWSKI MARKChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001209191-20-016871 · doc4.xml · derivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of March 1, 2019 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| March 01, 2019 Filed Mar 6, 2020 19:06 UTC |
Holmlin R. ErikDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 145,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001209191-20-016870 · doc4.xml · derivative · entry 1 Holmlin R. Erik · CIK 0001579988 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of March 1, 2019 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 02:08 UTC |
OLDAKOWSKI MARKChief Operating Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001209191-19-004894 · doc4.xml · derivative · entry 2 Borodkin Mark · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,219 Underlying: Common Stock · 6,000 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares vested on February 7, 2017, and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 02:08 UTC |
OLDAKOWSKI MARKChief Operating Officer
|
Exercise / conversionCommon Stock | 6,000 | $1.30 | $7,800.00 |
DisclosureSEC source: 0001209191-19-004894 · doc4.xml · nonDerivative · entry 1 Borodkin Mark · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 16:30 UTC |
Robinson WarrenChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 64,640 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-18-053811 · doc4.xml · derivative · entry 1 Robinson Warren · CIK 0001745569 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,640 Underlying: Common Stock · 64,640 shares Expires 2028-09-30 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on October 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:48 UTC |
OLDAKOWSKI MARKChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 59,590 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-18-053866 · doc4.xml · derivative · entry 1 Borodkin Mark · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,590 Underlying: Common Stock · 59,590 shares Expires 2028-09-30 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on October 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.